Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Biote (BTMD) Long-Term Debt Repayments (2021)

Biote has reported Long-Term Debt Repayments over the past 1 years, most recently at $164000.0 for Q1 2021.

Quarterly results put Long-Term Debt Repayments at $164000.0 for Q1 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was $164000.0 (changed N/A YoY), and the annual figure for FY2021 was $164000.0, changed.
Long-Term Debt Repayments for Q1 2021 was $164000.0 at Biote.
Over the last five years, Long-Term Debt Repayments for BTMD hit a ceiling of $164000.0 in Q1 2021 and a floor of $164000.0 in Q1 2021.